ENTA - Enanta Pharmaceuticals, Inc Price/Earnings to Growth Ratio

The PEG ratio dynamics demonstrate Enanta Pharmaceuticals' status as a respected developer of antiviral agents. The brand's high authority is bolstered by unique developments in viral replication and strategic partnerships. The current level of the 0.00 metric depends on the progress of clinical trials and capital adequacy. This chart helps determine the balance between the market price and the pace of business development.

Enanta Pharmaceuticals Inc. (ENTA): Price/Earnings to Growth Ratio from 07/04/2022 to 11/14/2026

Metric breakdowns and analytics for Enanta Pharmaceuticals (ENTA)

- share price and consensus valuation forecast:

Price Performance Chart Enanta Pharmaceuticals Inc.|ENTA - Consensus Target

- market capitalization statistics:

Market Value Enanta|ENTA - Enterprise Value

- issuer book value statistics:

Net Assets per Share Enanta Pharmaceuticals|ENTA - Company Book Value|Market Value to Book Value enanta.com|ENTA - Cumulative Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

ENTA - Company Net Income|Net Profit Forecast Enanta Pharmaceuticals|ENTA - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Enanta Pharmaceuticals, Inc|ENTA - PEG Multiple|EV/EBITDA Multiple Enanta|ENTA - Operating profit before deduction of amortization|Earnings per share for the trailing year Enanta Pharmaceuticals|ENTA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months enanta.com|ENTA - Earnings growth in current year|Expected earnings per share trend next year Enanta Pharmaceuticals

- total revenue and sales volume data:

ENTA - Revenue and Sales Volume|Projected Sales Volume Enanta Pharmaceuticals Inc.|ENTA - Price-to-Revenue Ratio|Forward Price to Sales Enanta

General company analysis:ENTA - Enanta Pharmaceuticals Inc.

Signature product of Enanta Pharmaceuticals, Inc.

The long-term reliability of Enanta Pharmaceuticals (ENTA) is based on the business's ability to generate profit faster than the growth of its market value, which is reflected in this weighted P/E relative to earnings growth rates. A value below one indicates that the asset is undervalued, confirming that the diversification of research in liver and respiratory therapies effectively mitigates the risks of individual project failures, creating potential for alpha.

Competitors of Enanta Pharmaceuticals